AI-Powered Test Offers Automated Quantitative Analysis of Fibrosis Assessment
Posted on 14 Aug 2025
Metabolic Dysfunction-associated Steatohepatitis (MASH) is a progressive form of liver disease that can lead to fibrosis, cirrhosis, liver failure, and an increased risk of liver cancer. Diagnosis relies on liver biopsy, with histological scoring systems often used in clinical trials to assess severity and treatment response. These methods can miss the disease’s complex, heterogeneous nature, creating a need for more accurate and reliable tools. Now, a new test offers automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with MASH.
HistoIndex (Singapore, Singapore) has launched the FibroSIGHT Plus test, which is designed to address diagnostic gaps. Building on the earlier FibroSIGHT, this new version adds automated quantitative fibrosis analysis to provide more precise characterization at diagnosis and during follow-up. The test is powered by qFibrosis, a proprietary AI algorithm that leverages stain-free Second Harmonic Generation imaging.
qFibrosis automatically quantifies multiple collagen architectural and morphological features from MASH liver biopsies, translating them into a single continuous fibrosis score. This allows clinicians to detect subtle changes in disease severity and gain detailed insights across various spatial zones of the biopsy. By providing measurements on a continuous scale rather than discrete categories, the tool supports more nuanced patient assessment.
Unlike conventional pathology methods that can be affected by staining inconsistencies and subjective interpretation, FibroSIGHT Plus offers a standardized, objective measurement across the entire specimen. It delivers granular measurements at single-fiber resolution on the full fibrosis spectrum, reducing inter-reader variability and enhancing diagnostic confidence. The system’s alignment with expert pathologist consensus demonstrates greater consistency than traditional histology, further strengthening its clinical reliability.
The technology enables earlier, targeted interventions by detecting incremental changes in fibrosis with high sensitivity. This could transform MASH patient management, supporting personalized, data-driven treatment decisions. HistoIndex aims to integrate the solution into routine care, with ongoing innovation to advance AI-powered digital pathology for chronic liver diseases.
"Automated solutions like FibroSIGHT Plus represent the future of liver pathology. The ability to detect incremental changes in fibrosis with this level of precision is exactly what we need to guide earlier and more targeted interventions in MASH," said Dr. Naim Alkhouri, Chief Academic Officer at Summit Clinical Research and Director of the Steatotic Liver Disease Program at the Clinical Research Institute of Ohio.
Related Links:
HistoIndex
